Regular ArticleThe use of a prognostic table to aid decision making on adjuvant therapy for women with early breast cancer
References (11)
A prognostic table to guide practitioners advising patients on adjuvant systemic therapy in early breast cancer
Eur J Surg Oncol
(1999)- et al.
The effect of physician recommendation on enrolment in the breast cancer chemoprevention trial
Prevent Med
(1998) Lancet
(1998)Lancet
(1998)- et al.
The Nottingham Prognostic Index
Breast Cancer Res Treat
(1992)
Cited by (20)
A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation
2016, International Journal of CardiologyCitation Excerpt :In conclusion, our findings, either showing an advantage over the actual practice of the model versions that would treat the highest proportion of patients, or showing the advantage of a decisional strategy that does not formally include the bleeding risk assessment, point out the need of educational interventions and support to counteract the concern about anticoagulation. On the other end, we want to emphasize that as with any impact study, even when randomized, this by definition evaluates the impact of a decisional model on average, i.e. at a population level [9,26,27]. At the individual level, a decisional strategy that takes into account whenever possible the specific patient's risks, needs, and preferences sounds always as the most appropriate one.
The use of patient and provider perspectives to develop a patient-oriented website for women diagnosed with breast cancer
2008, Patient Education and CounselingRevised prognostic table to guide practitioners advising patients on adjuvant systematic therapy in early breast cancer
2007, European Journal of Surgical OncologySurvival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999
2007, European Journal of CancerCitation Excerpt :Allied to that, case survival has risen. As the NPI is widely used in clinical practice,15 in the estimation of causation in legal reports and as the best present gold standard as a basis of comparison for new prognostic methods,8 there has been a good deal of demand for figures based on modern day diagnosis and case management to be provided. Updated survival figures on the whole Nottingham-Tenovus series (1973–2000) and on cancers treated in 1990–1999 were reported in an invited paper over-viewing the NPI in 2002.16
Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: An increase in cell number at completion of therapy is a predictor of early relapse
2007, BreastCitation Excerpt :This is within the same range as usually expected in comparable populations.1 According to their risk profile20 patients with good prognostic parameters (N0) were treated with EC only, whereas patients with inferior prognostic parameters (N1) received additional taxol cycles21 or CMF. Early relapses have so far occurred only in the patients with less favourable prognostic markers during the observation time of up to 4.5 years.
- f1
Correspondence to: Melanie Feldman, c/o Miss A Stotter, Dept. General Surgery, Glenfield Hospital, Groby Road, Leicester LE3 9PQ, UK. E-mail: [email protected]